FDA’s Yim On What The Future Holds For Biosimilars In 2026

US Biosimilars Are ‘Over The Hump, And About To Pick Up Speed’

 
• By Dave Wallace
  
Yim foresees an acceleration for biosimilars this year (Shutterstock)

More from Biosimilars

More from Products